A huge thank you to everyone who took part in the process. Our priority setting partnership has agreed on the uncertainties based on the input from patients, carers, and healthcare professionals.Download The Full Report
The James Lind Alliance (JLA) is a non-profit making initiative, which was established in 2004. It brings patients, carers and clinicians together to identify and prioritise the top 10 uncertainties, or 'unanswered questions', about the effects of treatments that they agree are most important.
What is UK DUETs?
The UK Database of Uncertainties about the Effects of Treatments (UK DUETs) publishes treatment uncertainties from patients, carers, clinicians, and from research recommendations, covering a wide variety of health problems.
The Cochrane Collaboration is an international organisation, and its business is to provide reliable information, not to offer practice or policy advice as if this could be applied universally. To help ensure that administered treatments do more good than harm, gaps in knowledge about their effects – uncertainties – must be identified, and those deemed sufficiently important must be addressed.
Patients and the public have a right to expect that research funders, researchers and health professionals are aware of uncertainties about the effects of treatments. Knowing about uncertainties tells us where further research is needed. Ignoring treatment uncertainties puts patients at risk. By making uncertainties known:
The JLA definition of a treatment uncertainty is that:
It can include other health care interventions, including prevention, testing and rehabilitation.
The questions that come in will be sorted and categorised by Neuro-Oncology JLA management staff (link) and then be prioritised by focussed groups and prioritised by the Neuro-Oncology Steering Group and Stakeholders to get "the 10 most important unanswered questions".